<DOC>
	<DOCNO>NCT02186574</DOCNO>
	<brief_summary>The purpose study determine effective preemptive tenofovir therapy prevent re-activation Hepatitis B infection , patient receive rituximab-based chemotherapy Non-Hodgkin 's Lymphoma . The rate re-activation compare patient receive preemptive tenofovir patient receive tenofovir need .</brief_summary>
	<brief_title>Tenofovir Prevent HBV Reactivation</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . â‰¥ 18 year age 2 . Diagnosis nonHodgkin 's lymphoma treat rituximabbased chemotherapy 3 . HBsAg negative , antiHBc positive 1 . Current therapy know activity HBV 2 . Screening ALT &gt; 10 x ULN 3 . Screening ALT &gt; 2 &lt; 10 xULN HBV DNA &gt; 2000 IU/mL ( indicate active HBV infection despite HBsAg negative require antiviral therapy ) 4 . Life expectancy &lt; 3 month 5 . HBsAg positive 6 . HIV coinfection 7 . Active HCV coinfection ( HCV RNA positive ) 8 . Creatinine clearance &lt; 50 mL/min 9 . Intolerance tenofovir 10 . Women childbearing potential unwilling take contraception study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Non-Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Viread</keyword>
</DOC>